Four Decades Inside Medical Technology
Thom Gunderson is a medical technology analyst and public company director whose career has run through the companies, the capital markets and the boardrooms of the medical device industry.
From 1992 through 2016 he was a Managing Director and senior research analyst at Piper Jaffray, covering medical technology companies in the public markets. His work focused on the questions that determine how sophisticated investors assess a business: product differentiation, clinical evidence, competitive position, management execution, growth durability and valuation.
Before Piper Jaffray he spent thirteen years at American Medical Systems, from 1979 to 1992, including as Project Director, remaining through the company’s acquisition by Pfizer in 1983. He came to the capital markets from inside the industry rather than from outside it.
His board service and biography are matters of public record in proxy statements filed with the U.S. Securities and Exchange Commission. Windsor Drake links to those filings directly rather than summarizing them, for the reason set out below.
The Practice
Windsor Drake represents founders and owners in the sale of their companies. Thom Gunderson advises the mandates where the company being sold is a medical device, diagnostics or healthcare technology business, and where the outcome turns on how buyers read the clinical and competitive evidence.
He pressure-tests the equity story before a buyer does. He helps distinguish durable product and clinical advantages from features buyers will discount, assesses strategic buyer fit, refines valuation and competitive positioning, and prepares management for the questions that surface in buyer review and diligence.
His perspective translates the underlying quality of a medical technology business into a transaction thesis that corporate development teams and boards can underwrite.
Where the Expertise Sits
Four vantage points matter in a medical technology sale. Thom Gunderson has worked from all four.
Clinical evidence and product differentiation
Medical technology buyers pay for evidence, not claims. Twenty-four years of covering the sector taught him which clinical data moves an acquirer’s model, which regulatory positions hold up under scrutiny, and where a claimed advantage is really a feature the market will compete away. Sellers who assemble that evidence before the process keep control of the narrative. Sellers who assemble it during diligence lose price.
The strategic buyer landscape
He spent more than two decades analyzing the acquirers themselves: how the major strategics build their corporate development pipelines, what gaps they are trying to fill, and how they justify a premium internally. That vantage point shapes buyer prioritization, which is where a process is won before it begins.
The public-market lens on valuation
Private sellers are ultimately priced against public comparables, because that is how a strategic acquirer’s board frames the decision. Having set and defended those frameworks in the public markets, he knows which metrics carry the argument and which are ignored.
Governance and the boardroom
He sits on the boards that approve transactions. He knows the questions a public company board asks before it authorizes an acquisition, because he is one of the people asking them.
Medical technology buyers do not pay for claims. They pay for evidence: clinical, commercial and competitive. The work is assembling that evidence before the first buyer conversation, not during diligence.
In the Boardroom
Thom Gunderson is an independent director of Merit Medical Systems, where he has served since May 2017. He chairs the Finance and Operating Committee and serves on the Compensation and Talent Development Committee. His current term runs to 2028.
He is an independent director of TransMedics Group, where he has served since August 2016. He chairs the Compensation Committee and serves on the Audit Committee, where the board has determined he is an audit committee financial expert as defined under Item 407 of Regulation S-K. He was re-elected to the TransMedics board on 20 May 2026.
He served on the American Heart Association’s Science and Technology Accelerator Committee from 2015 to 2017. He chairs the Minneapolis Heart Institute Foundation, where he has been a director since 2011 and served as chair from 2015 to 2020 and again since 2024, and he is an Executive in Residence at the University of Minnesota’s Medical Industry Leadership Institute.
Recognition and Public Record
His research was recognized by The Wall Street Journal, Institutional Investor, First Call and Thomson Reuters. As disclosed in Merit Medical Systems’ 2026 proxy statement, he was named a Wall Street Journal All-Star Analyst for medical stocks in 1996 and 2000 and Thomson Reuters’ top stock picker in the medical technology sector in 2014.
Windsor Drake links to the record rather than paraphrasing it. Credentials that cannot be checked are not credentials, and a firm asking to represent the largest transaction of an owner’s life should expect to be verified rather than believed. His board service, committee roles and biography are set out under the name Thomas J. Gunderson in Merit Medical Systems’ proxy statement and TransMedics Group’s proxy statement, both filed with the U.S. Securities and Exchange Commission in 2026.
- Public boards Merit Medical Systems (NASDAQ: MMSI) · TransMedics Group (NASDAQ: TMDX)
- Previously Managing Director and senior research analyst, Piper Jaffray, 1992 to 2016 · American Medical Systems, 1979 to 1992
- Sector coverage Medical devices, cardiovascular technology, surgical products, diagnostics, healthcare innovation
- Education B.A., Carleton College · M.S., cell biology, University of Minnesota · M.B.A., Opus College of Business, University of St. Thomas
- Based Minneapolis, advising medical technology companies throughout the United States
A Confidential Conversation
Owners of medical technology companies contact Windsor Drake at very different points: holding an unsolicited offer, a year out from a process, or simply wanting to understand what a buyer would find. Thom Gunderson advises those conversations directly.
Every conversation is confidential and carries no obligation. If a sale is not the right answer, the firm says so. Request a conversation, or read how the firm runs a process in How We Run a Sale.
